Operating Cash Flow per Share: A measure of financial performance calculated as operating cash flow, expressed on a per share basis. Calculated as: Cash Flow from Operations / Weighted Average Shares Outstanding (Diluted)
BioXcel Therapeutics, Inc. (BTAI) had Operating Cash Flow per Share of $-4.72 for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$0.26M |
|
$-12.54M |
|
$0.03M |
|
$0.22M |
|
$10.54M |
|
$-10.28M |
|
$-2.26M |
|
$-12.54M |
|
$-12.54M |
|
$-12.54M |
|
$-12.54M |
|
$-12.54M |
|
$-12.54M |
|
$-10.28M |
|
$-10.21M |
|
12.21M |
|
12.21M |
|
$0.40 |
|
$0.40 |
|
| Balance Sheet Financials | |
$44.69M |
|
$0.17M |
|
$0.23M |
|
$44.92M |
|
$53.93M |
|
$84.66M |
|
$86.45M |
|
$140.38M |
|
$-95.46M |
|
$-95.46M |
|
$-95.46M |
|
22.33M |
|
| Cash Flow Statement Financials | |
$-57.62M |
|
-- |
|
$56.52M |
|
$29.85M |
|
$28.76M |
|
$-1.10M |
|
$2.77M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.83 |
|
-- |
|
-- |
|
-7.84 |
|
-1.15 |
|
87.50% |
|
-4016.40% |
|
-4016.40% |
|
-- |
|
-4900.39% |
|
-4900.39% |
|
$-57.62M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
0.04 |
|
1.10 |
|
81.91 |
|
13.14% |
|
13.14% |
|
-27.93% |
|
116.16% |
|
$-4.28 |
|
$-4.72 |
|
|
Operating Cash Flow per Share |
$-4.72 |